Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Trehalose free)

As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2)

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK293

Origin Species

Mouse

Target

Spike RBD

Conjugation

Unconjugated

Tag

Human IgG1 | Human Kappa

Stability

For long term storage, the product is stable for up to 3 years at -70°C from date of receipt; For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt. Please avoid repeated freeze-thaw cycles.

Purity

0.95

Bioactivity

<strong>Detection SARS-CoV-2 S protein RBD by Sandwich ELISA Assay.</strong><br> Immobilized Anti-SARS-CoV-2 Spike S1 Antibody, chimeric mAb (Cat. No. S1N-M12A1) at 2 μg/mL (100 μL/well) can bind S protein RBD. And then add Anti-SARS-CoV-2 Spike S1 Antibody (Cat. No. S1N-M13A1) (Biotinylated in house) at 1:5000. Detection was performed using HRP-conjugated streptavidin with sensitivity of 25 pg/mL (Routinely tested).